Back to Search Start Over

SIRT1 regulates Mxd1 during malignant melanoma progression.

Authors :
Meliso FM
Micali D
Silva CT
Sabedot TS
Coetzee SG
Koch A
Fahlbusch FB
Noushmehr H
Schneider-Stock R
Jasiulionis MG
Source :
Oncotarget [Oncotarget] 2017 Oct 03; Vol. 8 (70), pp. 114540-114553. Date of Electronic Publication: 2017 Oct 03 (Print Publication: 2017).
Publication Year :
2017

Abstract

In a murine melanoma model, malignant transformation promoted by a sustained stress condition was causally related to increased levels of reactive oxygen species resulting in DNA damage and massive epigenetic alterations. Since the chromatin modifier Sirtuin-1 (SIRT1) is a protein attracted to double-stranded DNA break (DSB) sites and can recruit other components of the epigenetic machinery, we aimed to define the role of SIRT1 in melanomagenesis through our melanoma model. The DNA damage marker, γH2AX was found increased in melanocytes after 24 hours of deadhesion, accompanied by increased SIRT1 expression and decreased levels of its target, H4K16ac. Moreover, SIRT1 started to be associated to DNMT3B during the stress condition, and this complex was maintained along malignant progression. Mxd1 was identified by ChIP-seq among the DNA sequences differentially associated with SIRT1 during deadhesion and was shown to be a common target of both, SIRT1 and DNMT3B. In addition, Mxd1 was found downregulated from pre-malignant melanocytes to metastatic melanoma cells. Treatment with DNMT inhibitor 5AzaCdR reversed the Mxd1 expression. Sirt1 stable silencing increased Mxd1 mRNA expression and led to down-regulation of MYC targets, such as Cdkn1a, Bcl2 and Psen2, whose upregulation is associated with human melanoma aggressiveness and poor prognosis. We demonstrated a novel role of the stress responsive protein SIRT1 in malignant transformation of melanocytes associated with deadhesion. Mxd1 was identified as a new SIRT1 target gene. SIRT1 promoted Mxd1 silencing, which led to increased activity of MYC oncogene contributing to melanoma progression.<br />Competing Interests: CONFLICTS OF INTEREST This work does not present any conflicts of interest.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
70
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
29383100
Full Text :
https://doi.org/10.18632/oncotarget.21457